Vero Biotech, an Atlanta, GA-based commercial-stage healthcare business, raised $30M in funding.
The round was led by Petrichor. Patrick Lally, Partner of Petrichor, has joined the VERO Biotech Board of Directors.
The company intends to use the funds to support further development and commercialization of its GENOSYL Delivery System (DS), a tankless inhaled nitric oxide (iNO) delivery system.
Led by Brent V. Furse, CEO and President, Vero Biotech is a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community. GENOSYL DS is a tankless and portable system engineered with redundant backup features, which delivers a constant concentration of inhaled nitric oxide gas to patients with an easy-to-use interface and portability features. The third generation of the GENOSYL DS was recently approved by the FDA.
